REGENXBIO Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 90.24 million compared to USD 112.72 million a year ago. Net loss was USD 263.49 million compared to USD 280.32 million a year ago.

Basic loss per share from continuing operations was USD 6.02 compared to USD 6.5 a year ago. Diluted loss per share from continuing operations was USD 6.02 compared to USD 6.5 a year ago.